A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions

NCT07275814 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions

Interventions

DRUG: HRS-9231 Injection
DRUG: Gadobutrol Injection
DEVICE: Magnetic Resonance Imaging (MRI)

Sponsor

Shanghai Shengdi Pharmaceutical Co., Ltd